Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChimeriVax-WN02
- Development stage
- Phase 2
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ChimeriVax-WN02 is a live, attenuated recombinant vaccine developed for the prevention of West Nile virus infection. It is constructed using the yellow fever 17D vaccine strain as a backbone, with the premembrane (prM) and envelope (E) genes of West Nile virus inserted in place of those from yellow fever. This chimeric approach allows the vaccine to induce strong immune responses against West Nile virus while retaining the established safety profile of the yellow fever 17D platform. Clinical studies have shown that ChimeriVax-WN02 elicits robust neutralizing antibody and T cell responses in healthy adults across age groups, with a favorable safety profile. The primary indication is prevention of West Nile virus infection[1][3][6].
- Other names
- West Nile virus vaccine (ChimeriVax-WN02)Chimeric YF vector, WN prME
02
Targets
PSMB9 (Immunoproteasome subunit beta type-1i)
Beyond the preview
Go deeper on ChimeriVax-WN02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChimeriVax-WN02.